Table 3.
With STD in Group P (n:32) | Without STD in Group P (n:21) | p | |
---|---|---|---|
Demographic features | |||
Age [mean (± SD)] | 41.18(± 14.29) | 45.14(± 13.85) | 0.323a |
F/M (n) | 16/16 | 13/8 | 0.569e |
Comorbidities [n (%)] | |||
Hypertension | 6 (18.8) | 2 (9.5) | 0.455c |
Diabetes mellitus | 3 (9.4) | 2 (9.5) | 1.00c |
Chronic respiratory disease | 3 (9.4) | 1 (4.8) | 1.00c |
Neurologic disease | 1 (3.1) | 1 (4.8) | 1.00c |
Smoking | 10 (31.3) | 10 (47.6) | 0.361e |
Sinusitis/allergic rhinitis | 10 (31.3) | 4 (19) | 0.505e |
Head trauma | 3 (9.4) | 2 (9.5) | 1.00c |
Complaints when the sample received from the patient [n (%)] | |||
Fever | 20 (62.5) | 9 (42.9) | 0.261e |
Cough | 20 (62.5) | 8 (38.1) | 0.144e |
Sore throat | 4 (12.5) | 3 (14.3) | 1.00c |
Shortness of breath | 9 (28.1) | 6 (28.6) | 1.00e |
Headache | 12 (37.5) | 4 (19.0) | 0.260e |
Myalgia | 21 (65.6) | 6 (28.6) | 0.018e |
Malaise | 12 (37.5) | 8 (38.1) | 1.00e |
Nasal obstruction | 5 (15.6) | 1 (4.8) | 0.384c |
Rhinorrhea | 1 (3.1) | 0 (0) | 1.00c |
GIS symptoms | 10 (31.3) | 7 (33.3) | 1.00e |
Radiologic and labaratory findings | |||
Ground-glass apperance on CT [n (%)] | 21 (65.6) | 6 (28.6) | 0.018e |
CRP [median (min–max)] | 8.07 (1.0–349.0) | 3.14 (0.10–435.24) | 0.355d |
L [mean (± SD)] | 1.43 (± 0.85) | 2.10 (± 1.08) | 0.016a |
N/L [median (min–max)] | 2.24 (0.71–12.5) | 2.71 (1.30–29.40) | 0.940d |
Bold prints in ‘p’ column indicate a significant difference between with STD patients and without STD patients
% percentage, CRP C-reactive protein, COVID-19 coronavirus Didease 2019, CT computed tomography, F female, GIS gastrointestinal system, Group P COVID-19 positive patients, L lymphocyte count, M male, max maximum, min minimum, N/L neutrophil/lymphoctye ratio, SD standard deviation, STD smell/taste dysfunction
aindependent samples t test
bPearson chi square
cFisher exact test
dMann–Whitney U test
econtinuity correction